Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.58 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.48 |
| ▸ | CTSK | P43235 | 4/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 3/20 | 0.44 |
| ▸ | CTSS | P25774 | 3/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15095154 | 1.00 | SYK (0.58) | SYKKLK5CTSKTRPM8CTSL | |
| SCHEMBL7404713 | 0.91 | SYK (0.53) | SYKKLK5CTSKTRPM8CTSL | |
| SCHEMBL27658167 | 0.88 | SYK (0.55) | SYKKLK5CTSKTRPM8CTSL | |
| SCHEMBL27885868 | 0.88 | SYK (0.55) | SYKKLK5CTSKTRPM8CTSL | |
| SCHEMBL6612201 | 0.87 | SYK (0.49) | SYKKLK5CTSKTRPM8CTSL | |
| SCHEMBL6174500 | 0.85 | SYK (0.55) | SYKKLK5CTSKTRPM8CTSL | |
| SCHEMBL5499732 | 0.85 | SYK (0.55) | SYKKLK5CTSKTRPM8CTSL | |
| SCHEMBL30481176 | 0.85 | SYK (0.54) | SYKKLK5CTSKTRPM8CTSL | |
| SCHEMBL30481183 | 0.85 | SYK (0.54) | SYKKLK5CTSKTRPM8CTSL | |
| SCHEMBL30481184 | 0.85 | SYK (0.54) | SYKKLK5CTSKTRPM8CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129381-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090281128-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281128-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP5, CASP3 | SYK 1687/4885KLK5 792/4885CTSK 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.